Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

Browse trials for

• Depressive Disorder 4,845
• Depression 8,055
• Depressive Disorder, Major 2,740

Keywords

• ONO-2333Ms
• Major Depressive Disorder

Depressive Disorder

4,845 studies on the registry are indexed under Depressive Disorder; 514 are open to participants now.

This study's enrollment of 278 is above the median of 80 across 3,999 interventional studies indexed under Depressive Disorder.

Lead sponsor

Ono Pharma USA Inc is the lead sponsor of 21 studies on the registry; none are open to participants now.

Study arms

• Experimental
  Experimental 1

  1-2 mg of ONO-2333

  Drug: ONO-2333Ms Experimental 1

• Experimental
  Experimental 2

  5-10 mg of ONO-2333

  Drug: ONO-2333Ms Experimental 2

• Placebo comparator
  Placebo

  placebo comparator

  Drug: Placebo

Interventions

• DrugONO-2333Ms Experimental 2

  5-10 mg QD(once a day) for 8 weeks

• DrugPlacebo

  0 mg QD(once a day) for 8 weeks

• DrugONO-2333Ms Experimental 1

  1-2 mg QD(once a day) for 8 weeks

Primary outcomes

1. Change from baseline to treatment endpoint in the MADRS total score

   Time frame: 8 weeks

Secondary outcomes

1. Change from baseline to treatment endpoint in the HAM-D17, QIDS-SR16, CGI-S, CGI-I, PGI score

   Time frame: 8 weeks